The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes.
Roselle A HerringFariba Shojaee-MoradieMary StevenageIain ParsonsNicola JacksonJeewaka MendisBenita MiddletonA Margot UmplebyBarbara A FieldingMelanie DaviesDavid L Russell-JonesPublished in: Diabetes care (2022)
The increase in ketone enrichment from the ingested palmitic acid tracer suggests that meal-derived fatty acids contribute to the increase in ketones during treatment with dapagliflozin. The increase in BOHB concentration with dapagliflozin occurred with only minimal changes in plasma NEFA concentration and no change in lipolysis. This finding suggests a metabolic switch to increase ketogenesis within the liver.